This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fibach, E. Articles by Marks, P. A. Search for Related Content PubMed PubMed Citation Articles by Fibach, E. Articles by Marks, P. A.

Effect of Hexamethylene Bisacetamide on the Commitment to Differentiation of Murine Erythroleukemia Cells¹

Departments of Medicine and Human Genetics and Development, and the Cancer Research Center, Columbia University, New York, New York 10032

Friend virus-transformed murine erythroleukemia cells express the program of erythropoietic differentiation under the influence of the previously described, potent inducing agent, hexamethylene bisacetamide. Commitment to differentiation, defined as the ability to continue the processes of differentiation in the absence of inducer, has been examined at the single-cell level, with a combination of suspension and cell-cloning techniques. Recruitment of committed cells is shown to occur prior to the detectable accumulation of hemoglobin or the appearance of morphological changes characteristic of erythroid maturation. The stability of the commitment of murine erythroleukemia cells to differentiate is found to be dependent upon both the concentration of hexamethylene bisacetamide and the duration of exposure to the inducing agent. Under conditions less than optimal for induction, a single cell can give rise to a colony containing both differentiated and undifferentiated cells. On the basis of these findings, it is suggested that fully stabilized differentiation, in addition to the previously demonstrated requirement for the inducing agent to be present during a cell-cycle S phase, involves subsequent stabilizing event(s) caused by a direct or indirect action of the inducing agent.

¹ Supported in part by grants and contracts from the National Institutes of Health (GM-14552, CA-13696, CA-18316, NO1-CB-4-4008, NO1-CP-6-1008) and the National Science Foundation (NS7-PCM-75-08696).

² Fellow of the Schultz Foundation.

³ To whom requests for reprints should be addressed.

Received 8/20/76. Accepted 11/ 3/76.

This article has been cited by other articles:

				R. Sager Expression genetics in cancer: Shifting the focus from DNA to RNA PNAS, February 4, 1997; 94(3): 952 - 955. [Abstract] [Full Text] [PDF]

				T. Kume, T. Watanabe, R. Sanokawo, D. Chida, T. Nakamura, and M. Oishi Expression of the Protein Tyrosine Phosphatase beta 2 Gene in Mouse Erythroleukemia Cells Induces Terminal Erythroid Differentiation J. Biol. Chem., November 29, 1996; 271(48): 30916 - 30921. [Abstract] [Full Text] [PDF]

				S Salzberg, A Heller, J. Zou, F. Collart, and E Huberman Interferon-independent activation of (2'-5') oligoadenylate synthetase in Friend erythroleukemia cell variants exposed to HMBA J. Cell Sci., January 6, 1996; 109(6): 1517 - 1526. [Abstract] [PDF]